Genetic Disorder Clinical Trial
Official title:
Pilot Study to Assess Biomarkers of Changes in Barrier Function of Skeletal Muscle in Patients With a Fragile Sarcolemmal Muscular Dystrophy
Background: - Some kinds of muscular dystrophy affect the skeletal muscle membrane. In these conditions, the muscle membrane is more fragile. This affects how the muscles contract and relax, which causes movement problems. Researchers are looking at several muscle enzymes, or chemicals that affect how muscle cells function. By studying changes in these enzymes, they may be able to better understand how muscular dystrophy affects the cells. Researchers want to collect biomarkers (chemicals from blood samples) from people with fragile sarcolemmal muscular dystrophy. This information may provide better treatments for this condition. Objectives: - To study biomarkers that may affect the muscles of people with fragile sarcolemmal muscular dystrophy. Eligibility: - Individuals at least 18 years of age with fragile sarcolemmal muscular dystrophy. Design: - Participants will be screened with a medical history and physical exam. - Participants will be asked to come for four visits to the National Institutes of Health Clinical Center. The visits will be at least 2 months apart. Each visit will require participants to stay for 5 days at the clinical center. - During each visit, participants will provide frequent small blood samples. These samples will be collected while at rest and after physical exercise. - Participants will also have a physical therapy assessment. They will perform standard motor function tests and imaging tests (MRI, MRS). These tests may take up to 1 hour each time. - Treatment will not be provided as part of this study.
Objectives: the aim of this protocol is to identify biomarker and clinical correlates of changes in the barrier function of skeletal muscle membrane (i.e. cell membrane permeability) before and after routine motor function testing in patients with one of the Fragile Sarcolemmal Muscular Dystrophies (FSMD). Study population: patients with early adulthood or later onset of a FSMD (LGMD2B-F, I, L, MM, BMD, and MMD3). Study Phase: pilot study. Outcome measures: increased change in baseline levels of proteins that are released into the blood from damaged skeletal muscle, such as creatine kinase (CK), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), troponins, and myoglobin in serum, changes in inflammation markers, circulating microRNAs and imaging studies to identify effective biomarkers for use in future clinical trials. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01734486 -
Growth Response in Girls With Turner Syndrome
|
Phase 4 | |
| Completed |
NCT01529944 -
Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658
|
Phase 3 | |
| Completed |
NCT01518036 -
Use of Somatropin in Turner Syndrome
|
Phase 3 | |
| Completed |
NCT00025870 -
Studies of Children With Metabolic and Other Genetic Disorders
|
||
| Completed |
NCT01563926 -
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
|
Phase 3 | |
| Not yet recruiting |
NCT05737602 -
Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease
|
N/A | |
| Completed |
NCT01435629 -
A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin
|
N/A | |
| Completed |
NCT01245374 -
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
|
Phase 4 | |
| Terminated |
NCT01135537 -
Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants
|
Phase 2 | |
| Completed |
NCT00705172 -
Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome
|
||
| Completed |
NCT01518062 -
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
|
Phase 4 | |
| Recruiting |
NCT02769949 -
Pediatric Patients With Metabolic or Other Genetic Disorders
|
||
| Terminated |
NCT00358657 -
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders
|
Phase 2 | |
| Completed |
NCT01604161 -
Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome
|
N/A | |
| Completed |
NCT01516229 -
Special Survey for Long Term Application
|
N/A | |
| Recruiting |
NCT03093220 -
Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis
|
N/A | |
| Enrolling by invitation |
NCT04681781 -
SLC13A5 Deficiency Natural History Study - Remote Only
|
||
| Completed |
NCT01529840 -
Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome
|
Phase 3 | |
| Completed |
NCT01710696 -
Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome
|
Phase 3 | |
| Completed |
NCT01401244 -
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
|
Phase 1 |